[go: up one dir, main page]

WO2009151899A2 - Preparation of imatinib mesylate - Google Patents

Preparation of imatinib mesylate Download PDF

Info

Publication number
WO2009151899A2
WO2009151899A2 PCT/US2009/044587 US2009044587W WO2009151899A2 WO 2009151899 A2 WO2009151899 A2 WO 2009151899A2 US 2009044587 W US2009044587 W US 2009044587W WO 2009151899 A2 WO2009151899 A2 WO 2009151899A2
Authority
WO
WIPO (PCT)
Prior art keywords
imatinib mesylate
alpha
imatinib
crystalline
ether
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2009/044587
Other languages
French (fr)
Other versions
WO2009151899A3 (en
Inventor
Rajasekhar Kadaboina
Munaswamy Sekhar Nariyam
Vijay Bhailalbhai Patel
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Dr Reddys Laboratories Ltd
Dr Reddys Laboratories Inc
Original Assignee
Dr Reddys Laboratories Ltd
Dr Reddys Laboratories Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dr Reddys Laboratories Ltd, Dr Reddys Laboratories Inc filed Critical Dr Reddys Laboratories Ltd
Priority to EP09763190A priority Critical patent/EP2291366A4/en
Publication of WO2009151899A2 publication Critical patent/WO2009151899A2/en
Publication of WO2009151899A3 publication Critical patent/WO2009151899A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond

Definitions

  • the present application relates to a crystalline polymorphic form of imatinib mesylate.
  • Imatinib mesylate has a chemical name 4-[(4-Methyl-1-piperazinyl)methyl]- N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-phenyl]benzamide methanesulfonate and can be represented by structural Formula I.
  • Imatinib is a protein-tyrosine kinase inhibitor and is available in products sold by Novartis using the trademark GLEEVEC, in the form of tablets containing imatinib mesylate equivalent to 100 mg or 400 mg of imatinib free base.
  • Zimmermann et al. in U.S. Patent No. 6,894,051 , describe two crystalline forms of imatinib mesylate, the alpha-form and the beta-form.
  • the patent also discloses that the crystalline alpha-form is characterized by needle-shaped crystals having a hygroscopic nature and "the crystals are not particularly well- suited to pharmaceutical formulation as solid dosage forms, because their physical properties, for example their flow characteristics, are unfavorable and the alpha-crystal form is metastable at room temperature.
  • Example 1 of the patent discloses a process for preparing the crystalline alpha-form, which comprises: a. Suspending imatinib base in ethanol solvent; b. Adding methanesulfonic acid drop-wise into the suspension; c. Heating the solution to reflux and filtering at 65°C; d. Evaporating the filtrate to 50% of the volume; e. Cooling to 25°C and filtering; f. Collecting the solid (material A); g. Evaporating the mother liquor (filtrate) to dryness; h.
  • This process disclosed for preparing alpha crystalline form not only involves several steps, but also is cumbersome and does not give reproducible results.
  • Process 1 comprises:
  • Process 2 comprises:
  • Adin et al. in U.S. Patent Application Publication No. 2006/0223816 A1 ('"816" publication), describe a stable, free-flowing imatinib mesylate alpha-form, which is substantially free of the beta-form.
  • This publication describes a process, which comprises: a. Mixing imatinib base with an organic solvent selected from ketones, nithles and cycloalkanes (more particularly methyl ethyl ketone, methyl isobutyl ketone, 4-methylcyclohexanone, cyclohexane, acetonithle and mixtures thereof); b. Heating to dissolve; c. Adding methanesulfonic acid; d. Allowing the crystals to precipitate; e. Isolating the precipitated crystal of imatinib mesylate alpha-form, with seeding.
  • an organic solvent selected from ketones, nithles and cycloalkanes (more particularly
  • the present invention provides processes for preparing a non-hygroscopic, stable crystalline alpha-form of imatinib mesylate, comprising: a. Providing a solution or suspension of imatinib base in an ether solvent; b. Optionally, seeding with imatinib mesylate in alpha-form; c. Adding methanesulfonic acid; d. Allowing the reaction mass to cool; and e. Obtaining the alpha-form imatinib mesylate.
  • the present invention provides pharmaceutical compositions comprising stable crystalline alpha-form imatinib mesylate and at least one pharmaceutically acceptable excipient.
  • Fig. 1 is an X-Ray powder diffraction ("XRPD") pattern of the alpha-form of imatinib mesylate prepared according to Example 1.
  • Fig. 2 is an infrared (“IR”) absorption spectrum of the alpha-form of imatinib mesylate prepared according to Example 1.
  • Fig. 3 is a differential scanning calorimetry ("DSC") curve of the alpha-form of imatinib mesylate prepared according to Example 1.
  • Fig. 4 is a thermogravimetric analysis (“TGA”) curve of the alpha-form of imatinib mesylate prepared according to Example 1.
  • Fig. 5 is an XRPD pattern of the alpha-form of imatinib mesylate prepared according to Example 2.
  • Fig. 6 is an XRPD pattern of the alpha-form of imatinib mesylate of the present invention after one year of storage under ambient conditions.
  • Fig. 7 is an infrared (“IR”) absorption spectrum of imatinib mesylate of the present invention after one year of storage under ambient conditions.
  • Fig. 8 is a TGA curve of the alpha-form of imatinib mesylate of the present invention after one year of storage under ambient conditions.
  • Fig. 9 is a DSC curve of the alpha-form of imatinib mesylate of the present invention after one year of storage under ambient conditions.
  • Fig.10 is a TGA curve of the alpha-form of imatinib mesylate prepared according to Example 3.
  • the present application provides processes for preparing a stable crystalline alpha-form imatinib mesylate, using solvents comprising cyclic ethers and acyclic ethers.
  • crystalline alpha-form imatinib mesylate may be prepared from solvents comprising cyclic ethers and acyclic ethers, giving a product that is not only stable, but also non-hygroscopic, convenient to handle, and suitable for use in preparing solid pharmaceutical formulations.
  • the processes of the present invention include crystallizing imatinib mesylate from a solution having solvents comprising cyclic ethers and acyclic ethers, with imatinib and methanesulfonic acid dissolved therein, and optionally seeding with crystals of imatinib mesylate in alpha-form.
  • processes for preparing a non-hygroscopic and stable crystalline alpha-form imatinib mesylate comprising: a. providing a solution or suspension of imatinib base in an ether solvent; b. optionally, seeding with imatinib mesylate in alpha-form; c. adding methanesulfonic acid; and d. allowing the reaction mass to cool.
  • Step a includes providing a solution or suspension of imatinib base in an ether solvent.
  • the process of suspending the imatinib base in an ether solvent comprises combining imatinib base with the solvent.
  • the suspension of imatinib base may also be obtained directly from a reaction in which imatinib base is synthesized.
  • Solvents which may be used for suspending imatinib base include but are not limited to cyclic ethers and acyclic ethers. Specific examples of solvents that may be utilized for the present invention include cyclic ethers such as tetrahydrofuran ("THF"), pentahydropyran, and the like, and acyclic ether solvents such as dimethyl ether, diethyl ether, methyl t-butyl ether, and the like.
  • THF tetrahydrofuran
  • pentahydropyran and the like
  • acyclic ether solvents such as dimethyl ether, diethyl ether, methyl t-butyl ether, and the like.
  • the temperatures to which the suspension of imatinib base in a solvent can be heated may range from about 25°C to about 100 0 C, depending on the solvent used.
  • the suspension of imatinib mesylate in a solvent may also result in a solution, depending on the temperature to which it is heated.
  • the process of the present invention is carried out at temperatures in the range of about 40-70 0 C.
  • the quantities of solvent used for providing the suspension or solution depend on the solvent and the temperature adopted.
  • the concentration of imatinib base in the suspension may generally range from about 0.03 to about 0.1 g/mL.
  • seeding with imatinib mesylate is optional.
  • the alpha crystalline form obtained from a process disclosed in the art or from the process of the present invention may be used as a seed material.
  • Seeding with crystalline alpha form imatinib mesylate is carried out before or after the addition of methanesulfonic acid and after providing a solution or suspension of imatinib base in the ether solvent. In an embodiment, seeding with crystalline alpha-form of imatinib mesylate is carried out before the addition of methanesulfonic acid.
  • the quantity of the seed crystals used herein may be in the range of about 1 -8% by weight of alpha-form seeding material, based on the weight of suspended imatinib free base.
  • Step c includes adding methanesulfonic acid.
  • Isolation of the crystalline alpha-form obtained in step d can be accomplished by techniques known in art, which include but are not limited to decantation, filtration by gravity or by suction, distillation, centhfuging, slow solvent evaporation, and the like.
  • the obtained alpha-form of the present invention is isolated by filtration.
  • the isolated solid may optionally be further dried. Drying may be suitably carried out using equipment such as a tray dryer, vacuum oven, air oven, fluidized bed dryer, spin flash dryer, flash dryer and the like. The drying may be carried out at temperatures about 35°C to about 90 0 C, with or without vacuum. Drying may be carried out for any desired time until the desired product purity is achieved, such as time periods from about 1 to 20 hours, or longer.
  • the solid obtained is dried at temperatures ranging from about 30°C to about 60°C, or at temperatures about 40 0 C to about 45°C, under vacuum for a period of 2-3 hours.
  • Embodiments of the process provide imatinib mesylate alpha-form having a purity, as determined using high performance liquid chromatograpgy, at least about 98%, at least about 99%, at least about 99.5%, or at least about 99.8%, by weight.
  • the present invention provides processes for preparing substantially anhydrous crystalline alpha-form imatinib mesylate, comprising slurrying imatinib mesylate in a hydrocarbon solvent, followed by isolating the solid and drying.
  • the substantially anhydrous crystalline alpha-form imatinib mesylate obtained by the process has a TGA weight loss (from ambient temperature to about 150 0 C, or to about 200 0 C) less than about 0.5%, which may include water content and other volatile substances that are present.
  • a substantially anhydrous crystalline alpha-form imatinib mesylate has a TGA weight loss less than about 0.2%, or less than about 0.1 %.
  • a crystalline alpha-form of imatinib mesylate obtained according to the processes of the present invention when packaged in a polyethylene bag that is sealed and placed inside another sealed polyethylene bag, is stable during storage at ambient temperature for at least about one year.
  • Stored crystalline alpha-form of imatinib mesylate of the present invention can be characterized by any one or more of: an XRPD diffraction pattern substantially in accordance with Fig. 6; a TGA curve substantially in accordance with Fig. 8; and a DSC curve substantially in accordance with Fig. 9.
  • crystalline alpha-form of imatinib mesylate obtained from a process of present invention has a particle size distribution with Di 0 less than about 10 ⁇ m, D 50 less than about 50 ⁇ m, and D 90 less than about 100 ⁇ m.
  • the formed crystals are filtered and dried under vacuum for about 14 hours at 40-45 0 C, to obtain 68.415 g of crystalline alpha- form imatinib mesylate having a purity of about 99.91 % by weight, as determined using high performance liquid chromatography.
  • the product obtained has the X- ray powder diffraction pattern shown in Fig. 1.
  • the product is also analyzed by IR spectrophotometry, DSC, and TGA, and the information obtained is shown in Figs. 2, 3, and 4, respectively.
  • EXAMPLE 2 PREPARATION OF CRYSTALLINE ALPHA-FORM IMATINIB MESYLATE.
  • Imatinib base (1.0 g) is added to THF (25 mL) and heated to about 55-60°C under a nitrogen atmosphere.
  • a solution of methanesulfonic acid (0.13 mL, 0.192 g) in THF (15 mL) is added slowly over 3 hours under a nitrogen atmosphere.
  • the mass is stirred for another 30 minutes at 55-60 0 C and cooled to 25°C.
  • the formed crystals are filtered and dried under vacuum for 1 hour at 40-45 0 C, to obtain 0.950 g of crystalline alpha-form imatinib mesylate.
  • the product obtained has the X-ray powder diffraction pattern shown in Fig. 5.
  • the crystalline alpha-form of imatinib mesylate obtained in the above example is stable during storage for at least one year, when packaged in a sealed polyethylene bag, and the X-ray powder diffraction pattern for material stored for one year is substantially as shown in Fig. 6.
  • the stored material provides an infrared absorption spectrum substantially as shown in Fig. 7, a thermogravimetric analysis curve substantially as shown in Fig. 8 (weight loss about 1 %) and a differential scanning calorimetry curve substantially as shown in Fig. 9 (major peak at about 220 0 C).
  • Alpha-form imatinib mesylate (5.0 g) is suspended in n-heptane (62.5 mL) and slurried for 45 minutes at room temperature under a nitrogen atmosphere. The suspension is filtered and the solid washed with n-heptane (12 mL). The solid is dried under vacuum for 3 hours at 40-45°C, to obtain 4.9 g of light yellow solid crystalline alpha-form imatinib mesylate that is substantially anhydrous. Analyses are reported in the following table. The TGA curve for the product is substantially as shown in Fig. 10.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

Processes for preparing a non-hygroscopic and stable crystalline alpha-form imatinib mesylate.

Description

PREPARATION OF IMATINIB MESYLATE
INTRODUCTION
The present application relates to a crystalline polymorphic form of imatinib mesylate.
Imatinib mesylate has a chemical name 4-[(4-Methyl-1-piperazinyl)methyl]- N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-phenyl]benzamide methanesulfonate and can be represented by structural Formula I.
Figure imgf000002_0001
Formula I
Imatinib is a protein-tyrosine kinase inhibitor and is available in products sold by Novartis using the trademark GLEEVEC, in the form of tablets containing imatinib mesylate equivalent to 100 mg or 400 mg of imatinib free base.
Zimmermann et al., in U.S. Patent No. 6,894,051 , describe two crystalline forms of imatinib mesylate, the alpha-form and the beta-form. The patent also discloses that the crystalline alpha-form is characterized by needle-shaped crystals having a hygroscopic nature and "the crystals are not particularly well- suited to pharmaceutical formulation as solid dosage forms, because their physical properties, for example their flow characteristics, are unfavorable and the alpha-crystal form is metastable at room temperature. At 25°C, the alpha-crystal form is hygroscopic and rapidly takes up water so that, at 93% relative humidity, the sample is to some extent present in amorphous form." Example 1 of the patent discloses a process for preparing the crystalline alpha-form, which comprises: a. Suspending imatinib base in ethanol solvent; b. Adding methanesulfonic acid drop-wise into the suspension; c. Heating the solution to reflux and filtering at 65°C; d. Evaporating the filtrate to 50% of the volume; e. Cooling to 25°C and filtering; f. Collecting the solid (material A); g. Evaporating the mother liquor (filtrate) to dryness; h. Suspending dried solid and material A in ethanol and dissolving under reflux with the addition of water. i. Cooling the solution overnight at 25°C. j. Filtering and drying at 65°C until a constant weight is achieved. k. Collecting light beige, crystalline imatinib mesylate (alpha-crystal form).
This process disclosed for preparing alpha crystalline form not only involves several steps, but also is cumbersome and does not give reproducible results.
International Application Publication No. WO 2005/077933 A1 describes an alpha 2 crystalline form of imatinib mesylate which is stable at room temperature and even at higher temperatures such as 1200C. The application provides two processes for the preparation of alpha 2-crystalline form of imatinib mesylate.
Process 1 comprises:
(i) Suspending imatinib base in isopropanol;
(ii) Adding methanesulfonic acid;
(iii) Refluxing the mixture;
(iv) Cooling and filtering to yield the alpha 2 form.
Process 2 comprises:
(a) Suspending beta-polymorphic compound in water and organic solvents such as methanol, isopropyl ether, toluene, cyclohexane and isopropyl alcohol.
(b) Distilling water azeotropically;
(c) Cooling the solution;
(d) Filtering the material to obtain the alpha 2 form.
Adin et al., in U.S. Patent Application Publication No. 2006/0223816 A1 ('"816" publication), describe a stable, free-flowing imatinib mesylate alpha-form, which is substantially free of the beta-form. This publication describes a process, which comprises: a. Mixing imatinib base with an organic solvent selected from ketones, nithles and cycloalkanes (more particularly methyl ethyl ketone, methyl isobutyl ketone, 4-methylcyclohexanone, cyclohexane, acetonithle and mixtures thereof); b. Heating to dissolve; c. Adding methanesulfonic acid; d. Allowing the crystals to precipitate; e. Isolating the precipitated crystal of imatinib mesylate alpha-form, with seeding.
The process described in the '816 publication necessarily involves seeding with an alpha-crystal form of imatinib mesylate and also involves the use of solvents like 4-methylcyclohexanone, which are not only expensive for industrial use but also not suitable for handling in industrial scale production.
Pathi et al., in U.S. Patent Application Publication No. 2007/0265288 A1 , describe a method of preparing crystalline imatinib mesylate alpha-form which involves the use of an alcoholic or ketonic solvent.
Szczepek et al., in U.S. Patent Application Publication No. 2007/0197545 A1 , describe a process for the preparation of alpha-crystal form of imatinib mesylate which involves the use of not more than 0.99 equivalents of methanesulfonic acid, per equivalent of imatinib, in a solvent selected from the group consisting of C2-C6 aliphatic alcohols and mixtures thereof, optionally with the addition of Ci-C4 aliphatic alcohols. The publication also discloses a process involving the use of solvents selected from the group consisting of esters of lower carboxylic acids and Ci-C4 aliphatic alcohols.
International Application Publication No. WO 2006/048890 A1 describes a non-needle shaped alpha-crystalline form of imatinib mesylate and a process for its preparation, which includes subjecting a solution of imatinib mesylate in a suitable solvent (which may be a polar protic or aprotic solvent, a non-polar solvent, water or mixture thereof) to agitated thin film drying under atmospheric pressure and/or under vacuum.
International Application Publication No. WO 2007/136510 A2 describes processes for preparing crystalline imatinib mesylate of form alpha comprising providing a solution of imatinib mesylate in ethylene glycol dimethyl ether, and admixing the solution with t-butyl methyl ether to form a suspension comprising the crystalline form, or slurrying other crystalline forms of imatinib mesylate in solvents selected from ethylacetate, n-propanol, acetone and mixtures thereof.
The above-mentioned documents collectively disclose diverse processes, but due to various reasons they are not particularly convenient and amenable to scale-up for preparing the stable alpha form. Thus, there is an unmet need in the field for the provision of simple, controlled procedures for the preparation of an alpha form of imatinib mesylate, which is not only stable but also amenable to scale-up and suitable for preparation of solid pharmaceutical dosage forms.
SUMMARY
In an embodiment, the present invention provides processes for preparing a non-hygroscopic, stable crystalline alpha-form of imatinib mesylate, comprising: a. Providing a solution or suspension of imatinib base in an ether solvent; b. Optionally, seeding with imatinib mesylate in alpha-form; c. Adding methanesulfonic acid; d. Allowing the reaction mass to cool; and e. Obtaining the alpha-form imatinib mesylate.
In another embodiment, the present invention provides process for preparing a stable crystalline alpha-form of imatinib mesylate wherein the process comprises providing a solution or suspension of imatinib mesylate in an ether solvent, followed by the steps c, d, and e described above.
In yet another embodiment, the present invention provides pharmaceutical compositions comprising stable crystalline alpha-form imatinib mesylate and at least one pharmaceutically acceptable excipient.
BRIEF DESCRIPTION OF THE DRAWINGS Fig. 1 is an X-Ray powder diffraction ("XRPD") pattern of the alpha-form of imatinib mesylate prepared according to Example 1.
Fig. 2 is an infrared ("IR") absorption spectrum of the alpha-form of imatinib mesylate prepared according to Example 1.
Fig. 3 is a differential scanning calorimetry ("DSC") curve of the alpha-form of imatinib mesylate prepared according to Example 1. Fig. 4 is a thermogravimetric analysis ("TGA") curve of the alpha-form of imatinib mesylate prepared according to Example 1.
Fig. 5 is an XRPD pattern of the alpha-form of imatinib mesylate prepared according to Example 2.
Fig. 6 is an XRPD pattern of the alpha-form of imatinib mesylate of the present invention after one year of storage under ambient conditions.
Fig. 7 is an infrared ("IR") absorption spectrum of imatinib mesylate of the present invention after one year of storage under ambient conditions.
Fig. 8 is a TGA curve of the alpha-form of imatinib mesylate of the present invention after one year of storage under ambient conditions.
Fig. 9 is a DSC curve of the alpha-form of imatinib mesylate of the present invention after one year of storage under ambient conditions.
Fig.10 is a TGA curve of the alpha-form of imatinib mesylate prepared according to Example 3.
DETAILED DESCRIPTION
The present application provides processes for preparing a stable crystalline alpha-form imatinib mesylate, using solvents comprising cyclic ethers and acyclic ethers.
The invention further provides a stable crystalline alpha-form imatinib mesylate, which is non-hygroscopic, convenient to handle, and suitable for preparation of solid pharmaceutical dosage forms.
A stable crystalline form of imatinib mesylate can be characterized by its X- ray powder diffraction pattern, as well as by other analytical techniques. All of the XRPD data reported herein were obtained using a Bruker AXS D8 Advance Powder X-ray Diffractometer with a copper K-alpha radiation source.
It has been found that crystalline alpha-form imatinib mesylate may be prepared from solvents comprising cyclic ethers and acyclic ethers, giving a product that is not only stable, but also non-hygroscopic, convenient to handle, and suitable for use in preparing solid pharmaceutical formulations.
The processes of the present invention include crystallizing imatinib mesylate from a solution having solvents comprising cyclic ethers and acyclic ethers, with imatinib and methanesulfonic acid dissolved therein, and optionally seeding with crystals of imatinib mesylate in alpha-form. In an embodiment of the present invention, there are provided processes for preparing a non-hygroscopic and stable crystalline alpha-form imatinib mesylate comprising: a. providing a solution or suspension of imatinib base in an ether solvent; b. optionally, seeding with imatinib mesylate in alpha-form; c. adding methanesulfonic acid; and d. allowing the reaction mass to cool.
Individual steps are further described separately herein below.
Step a includes providing a solution or suspension of imatinib base in an ether solvent.
Imatinib base used in the processes of the present invention can be obtained from processes disclosed in the art, for example U.S. Patent No. 5,521 ,184 or International Application No. PCT/US08/56588, filed on March 12, 2008, or any other processes. Any polymorphic form of the compound, such as crystalline or amorphous forms, including solvates and hydrates, may also be utilized.
The process of suspending the imatinib base in an ether solvent comprises combining imatinib base with the solvent.
The suspension of imatinib base may also be obtained directly from a reaction in which imatinib base is synthesized.
Solvents which may be used for suspending imatinib base include but are not limited to cyclic ethers and acyclic ethers. Specific examples of solvents that may be utilized for the present invention include cyclic ethers such as tetrahydrofuran ("THF"), pentahydropyran, and the like, and acyclic ether solvents such as dimethyl ether, diethyl ether, methyl t-butyl ether, and the like.
The temperatures to which the suspension of imatinib base in a solvent can be heated may range from about 25°C to about 1000C, depending on the solvent used. The suspension of imatinib mesylate in a solvent may also result in a solution, depending on the temperature to which it is heated. In an embodiment, the process of the present invention is carried out at temperatures in the range of about 40-700C. The quantities of solvent used for providing the suspension or solution depend on the solvent and the temperature adopted. The concentration of imatinib base in the suspension may generally range from about 0.03 to about 0.1 g/mL.
Step b includes optionally seeding with imatinib mesylate in alpha-form.
According to the present invention, seeding with imatinib mesylate is optional. However, if carried out, the alpha crystalline form obtained from a process disclosed in the art or from the process of the present invention may be used as a seed material.
Seeding with crystalline alpha form imatinib mesylate is carried out before or after the addition of methanesulfonic acid and after providing a solution or suspension of imatinib base in the ether solvent. In an embodiment, seeding with crystalline alpha-form of imatinib mesylate is carried out before the addition of methanesulfonic acid.
The quantity of the seed crystals used herein may be in the range of about 1 -8% by weight of alpha-form seeding material, based on the weight of suspended imatinib free base.
Step c includes adding methanesulfonic acid.
According to the present invention, the molar quantities of methanesulfonic acid that may be used are in the range of about 0.9 to about 1.1 moles, per mole of imatinib base. In embodiments, the molar quantity of methane sulfonic acid used is about 1 mole, per mole of imatinib base.
Methane sulfonic acid can be added in the form of solution or optionally dissolved in an ether solvent. The quantity of ether solvent used to prepare a solution of methanesulfonic acid may range between about 10 and about 25 ml_, per gram of imatinib base. In an embodiment, a volume of ether solvent may be about 15 ml_, per gram of imatinib base.
The temperatures at which methanesulfonic acid can be added to the mass of step b) may range from about 25°C to about 1000C. Any other temperatures may also be acceptable, as long as a solution or suspension of imatinib base is provided. In an embodiment, the process of the present invention is carried out at temperatures in the range of about 400C to about 70°C.
Step d includes allowing the mass to cool.
The mass obtained in step c is cooled to obtain the alpha-form of imatinib mesylate. The temperature to which the reaction mass is cooled may range from about 00C to about 35°C, depending on the solvent used. Any temperature is acceptable as long as the alpha-form of imatinib mesylate is obtained selectively and completely. In an embodiment, the cooling may be carried out to temperatures in the range of about 100C to about 300C.
The product may be obtained from step d by isolation, followed by drying the product.
Isolation of the crystalline alpha-form obtained in step d can be accomplished by techniques known in art, which include but are not limited to decantation, filtration by gravity or by suction, distillation, centhfuging, slow solvent evaporation, and the like. In embodiments, the obtained alpha-form of the present invention is isolated by filtration.
The isolated solid may optionally be further dried. Drying may be suitably carried out using equipment such as a tray dryer, vacuum oven, air oven, fluidized bed dryer, spin flash dryer, flash dryer and the like. The drying may be carried out at temperatures about 35°C to about 900C, with or without vacuum. Drying may be carried out for any desired time until the desired product purity is achieved, such as time periods from about 1 to 20 hours, or longer.
In embodiments, the solid obtained is dried at temperatures ranging from about 30°C to about 60°C, or at temperatures about 400C to about 45°C, under vacuum for a period of 2-3 hours.
Embodiments of the process provide imatinib mesylate alpha-form having a purity, as determined using high performance liquid chromatograpgy, at least about 98%, at least about 99%, at least about 99.5%, or at least about 99.8%, by weight.
In an embodiment, the present invention provides processes for preparing substantially anhydrous crystalline alpha-form imatinib mesylate, comprising slurrying imatinib mesylate in a hydrocarbon solvent, followed by isolating the solid and drying.
Hydrocarbon solvents that can be utilized include aliphatic hydrocarbons having 5-10 carbon atoms, and aromatic hydrocarbons having 6-10 carbon atoms. Mixtures of hydrocarbon solvents are useful. Specific examples of some useful hydrocarbons are n-hexane and n-heptane.
The substantially anhydrous crystalline alpha-form imatinib mesylate obtained by the process has a TGA weight loss (from ambient temperature to about 1500C, or to about 2000C) less than about 0.5%, which may include water content and other volatile substances that are present. In embodiments, a substantially anhydrous crystalline alpha-form imatinib mesylate has a TGA weight loss less than about 0.2%, or less than about 0.1 %.
The substantially anhydrous product obtained is a stable crystalline alpha- form of imatinib mesylate, which is non-hygroscopic, convenient to handle, and suitable for preparation of solid pharmaceutical dosage forms.
Imatinib mesylate used as a starting material in the processes can be obtained using a process disclosed in the art, e.g., U.S. Patent No. 6,894,051 , or any other process. Any polymorphic form of imatinib mesylate may be used in the preparation of alpha-form of the present invention.
A crystalline alpha-form of imatinib mesylate obtained according to the processes of the present invention, when packaged in a polyethylene bag that is sealed and placed inside another sealed polyethylene bag, is stable during storage at ambient temperature for at least about one year. Stored crystalline alpha-form of imatinib mesylate of the present invention can be characterized by any one or more of: an XRPD diffraction pattern substantially in accordance with Fig. 6; a TGA curve substantially in accordance with Fig. 8; and a DSC curve substantially in accordance with Fig. 9.
In an embodiment, crystalline alpha-form of imatinib mesylate obtained from a process of present invention has a particle size distribution with Di0 less than about 10 μm, D50 less than about 50 μm, and D90 less than about 100 μm.
The Dio, D50 and D90 values are useful ways for indicating a particle size distribution. D90 refers to a particle size value for which at least 90 volume percent of the particles have a size smaller than the value given. Likewise D50 and Di0 refer to the values for the particle size for which 50 volume percent, and 10 volume percent, respectively, of the particles have a size smaller than the value given.
In an embodiment, the present invention provides pharmaceutical formulations comprising a stable crystalline alpha-form of imatinib mesylate and one or more pharmaceutically acceptable excipients.
Suitable pharmaceutically acceptable excipients which can be used in combination with imatinib mesylate include, but are not limited to, hydrophilic substances like polymers of N-vinylpyrrolidone, commonly known as polyvinyl pyrrolidines ("PVP" or "povidone"), gums, cellulose derivatives, cyclodextrins, gelatins, hypromellose phthalates, sugars, polyhydric alcohols, polyethylene glycols, polyethylene oxides, polyoxyalkylene derivatives, methacrylic acid copolymers, polyvinylalcohols, propylene glycol derivatives and the like. Other pharmaceutically acceptable excipients that are of use include, but are not limited to, film formers, plasticizers, colorants, flavoring agents, sweeteners, viscosity enhancers, preservatives, antioxidants and the like.
Certain specific aspects and embodiments of the invention will be further described by the following examples. The examples are provided solely for purposes of illustration, and should not be construed as limiting the scope of the invention in any manner. It will be apparent to those skilled in the art that many modifications, both to materials and methods, may be practiced without departing from the scope of the invention.
EXAMPLE 1 : PREPARATION OF CRYSTALLINE ALPHA-FORM IMATINIB MESYLATE. lmatinib base (70.0 g) is added to THF (1750 mL), heated to about 55-600C under a nitrogen atmosphere to form a solution having some turbidity, and seeded with crystalline alpha-form imatinib mesylate (1.0 g, 1.42% w/w). A solution of methanesulfonic acid (9.2 mL, 13.628 g) in THF (1050 mL) is added slowly over 3 hours under a nitrogen atmosphere. The mass is stirred for another 30 minutes at 55-600C and cooled to 27°C. The formed crystals are filtered and dried under vacuum for about 14 hours at 40-450C, to obtain 68.415 g of crystalline alpha- form imatinib mesylate having a purity of about 99.91 % by weight, as determined using high performance liquid chromatography. The product obtained has the X- ray powder diffraction pattern shown in Fig. 1. The product is also analyzed by IR spectrophotometry, DSC, and TGA, and the information obtained is shown in Figs. 2, 3, and 4, respectively.
EXAMPLE 2: PREPARATION OF CRYSTALLINE ALPHA-FORM IMATINIB MESYLATE.
Imatinib base (1.0 g) is added to THF (25 mL) and heated to about 55-60°C under a nitrogen atmosphere. A solution of methanesulfonic acid (0.13 mL, 0.192 g) in THF (15 mL) is added slowly over 3 hours under a nitrogen atmosphere. The mass is stirred for another 30 minutes at 55-600C and cooled to 25°C. The formed crystals are filtered and dried under vacuum for 1 hour at 40-450C, to obtain 0.950 g of crystalline alpha-form imatinib mesylate. The product obtained has the X-ray powder diffraction pattern shown in Fig. 5.
The crystalline alpha-form of imatinib mesylate obtained in the above example is stable during storage for at least one year, when packaged in a sealed polyethylene bag, and the X-ray powder diffraction pattern for material stored for one year is substantially as shown in Fig. 6. The stored material provides an infrared absorption spectrum substantially as shown in Fig. 7, a thermogravimetric analysis curve substantially as shown in Fig. 8 (weight loss about 1 %) and a differential scanning calorimetry curve substantially as shown in Fig. 9 (major peak at about 2200C).
EXAMPLE 3: PREPARATION OFANHYDROUS CRYSTALLINE ALPHA-FORM IMATINIB MESYLATE.
Alpha-form imatinib mesylate (5.0 g) is suspended in n-heptane (62.5 mL) and slurried for 45 minutes at room temperature under a nitrogen atmosphere. The suspension is filtered and the solid washed with n-heptane (12 mL). The solid is dried under vacuum for 3 hours at 40-45°C, to obtain 4.9 g of light yellow solid crystalline alpha-form imatinib mesylate that is substantially anhydrous. Analyses are reported in the following table. The TGA curve for the product is substantially as shown in Fig. 10.
Figure imgf000012_0001

Claims

CLAIMS:
1. A process for preparing crystalline imatinib mesylate alpha-form, comprising: a. providing a solution or suspension of imatinib base in an ether solvent; b. optionally, seeding with imatinib mesylate in alpha-form; c. adding methanesulfonic acid; and d. cooling the mixture.
2. The process of claim 1 , wherein an ether solvent comprises a cyclic ether, an acyclic ether, or a mixture thereof.
3. The process of claim 1 , wherein an ether solvent comprises a cyclic ether.
4. The process of claim 1 , wherein an ether solvent comprises tetrahydrofuran.
5. The process of claim 1 , wherein a solution or suspension of imatinib base in ether solvent is provided at temperatures about 300C to about 65°C.
6. The process of claim 1 , wherein the seeding comprises adding about 1 to about 8 percent by weight of imatinib mesylate alpha-form, based on the starting weight of imatinib base.
7. The process of claim 1 , wherein molar ratios of imatinib base to methanesulfonic acid are about 1 :0.9 to about 1 :1.1.
8. The process of claim 1 , wherein the mass is cooled to temperatures below about 300C.
9. The process of claim 1 , further comprising isolating a solid product and drying.
10. The process of claim 1 , wherein the crystalline imatinib mesylate alpha-form has a purity greater than about 99.8 percent by weight.
11. Imatinib mesylate alpha-form, prepared by a process of any of claims 1 -10.
12. A process for preparing substantially anhydrous crystalline imatinib mesylate alpha-form, comprising slurrying imatinib mesylate in a hydrocarbon solvent.
13. The process of claim 12, wherein a hydrocarbon solvent comprises an aliphatic hydrocarbon having 5-10 carbon atoms.
14. The process of claim 12, wherein a hydrocarbon solvent comprises n-hexane or n-heptane.
15. Substantially anhydrous imatinib mesylate alpha-form, prepared by a process of any of claims 12-14.
16. Substantially anhydrous crystalline imatinib mesylate alpha-form having a weight loss by thermogravimetric analysis, between ambient temperature and about 1500C, less than about 0.5 percent.
17. Substantially anhydrous crystalline imatinib mesylate alpha-form of claim 16, having a weight loss less than about 0.2 percent.
18. Substantially anhydrous crystalline imatinib mesylate alpha-form of claim 16, having a weight loss less than about 0.1 percent
PCT/US2009/044587 2008-05-26 2009-05-20 Preparation of imatinib mesylate Ceased WO2009151899A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP09763190A EP2291366A4 (en) 2008-05-26 2009-05-20 Preparation of imatinib mesylate

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
IN1285CH2008 2008-05-26
IN1285/CHE/2008 2008-05-26
US9800308P 2008-09-18 2008-09-18
US61/098,003 2008-09-18

Publications (2)

Publication Number Publication Date
WO2009151899A2 true WO2009151899A2 (en) 2009-12-17
WO2009151899A3 WO2009151899A3 (en) 2010-02-25

Family

ID=41417346

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2009/044587 Ceased WO2009151899A2 (en) 2008-05-26 2009-05-20 Preparation of imatinib mesylate

Country Status (2)

Country Link
EP (1) EP2291366A4 (en)
WO (1) WO2009151899A2 (en)

Cited By (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011108953A1 (en) * 2010-03-04 2011-09-09 Tomasz Kozluk PROCESS FOR PREPARATION OF POLYMORPHIC FORM α AND NEW POLYMORPHIC FORM OF IMATINIB MESYLATE ISOLATED IN THAT PROCESS
WO2011158255A1 (en) * 2010-06-16 2011-12-22 Aptuit Laurus Private Limited Process for preparation of stable imatintb mesylate alpha form
WO2011157450A1 (en) 2010-06-18 2011-12-22 Krka, D. D., Novo Mesto New polymorphic form of imatinib base and preparation of salts thereof
WO2012014000A1 (en) * 2010-07-30 2012-02-02 Ramesh Babu Potluri STABLE α-CRYSTAL FORM OF IMATINIB MESYLATE AND PREPARING PROCESS THEREOF
WO2012071980A1 (en) * 2010-11-30 2012-06-07 浙江九洲药业股份有限公司 Preparation method of α-imatinib mesylate
WO2012015999A3 (en) * 2010-07-29 2012-08-30 Dr. Reddy's Laboratories Ltd. Process for the preparation of imatinib mesylate
EP2546247A1 (en) 2011-07-14 2013-01-16 F.I.S.- Fabbrica Italiana Sintetici S.p.A. Imatinib mesylate preparation procedure
WO2013136141A1 (en) 2012-03-13 2013-09-19 Fresenius Kabi Oncology Ltd. An improved process for the preparation of alpha form of imatinib mesylate
EP2749557A1 (en) 2012-12-31 2014-07-02 Deva Holding Anonim Sirketi Process for preparation of alpha polymorph of imatinib mesylate from IPA and THF solvate forms of imatinib mesylate
US8912325B2 (en) 2011-03-31 2014-12-16 Ind-Swift Laboratories Limited Process for preparation of imatinib and its mesylate salt
EP2927223A1 (en) 2014-04-04 2015-10-07 F.I.S.- Fabbrica Italiana Sintetici S.p.A. Process for preparing imatinib and salts thereof, free of genotoxic impurity f
EP3007699A4 (en) * 2013-06-12 2017-01-18 Shilpa Medicare Limited Crystalline imatinib mesylate process

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TR200504337T1 (en) * 2003-06-02 2006-12-21 Hetero Drugs Limited New polymorphs of Imatinib mesylate
TR200701870T1 (en) * 2004-09-02 2007-05-21 Cipla Limited The stable crystalline form of imatinib mesylate and the process for its preparation.
US8067421B2 (en) * 2006-04-27 2011-11-29 Sicor Inc. Polymorphic forms of imatinib mesylate and processes for preparation of novel crystalline forms as well as amorphous and form α
US20060223816A1 (en) * 2006-05-08 2006-10-05 Chemagis Ltd. Imatinib mesylate alpha form and production process therefor

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of EP2291366A4 *

Cited By (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011108953A1 (en) * 2010-03-04 2011-09-09 Tomasz Kozluk PROCESS FOR PREPARATION OF POLYMORPHIC FORM α AND NEW POLYMORPHIC FORM OF IMATINIB MESYLATE ISOLATED IN THAT PROCESS
WO2011158255A1 (en) * 2010-06-16 2011-12-22 Aptuit Laurus Private Limited Process for preparation of stable imatintb mesylate alpha form
WO2011157450A1 (en) 2010-06-18 2011-12-22 Krka, D. D., Novo Mesto New polymorphic form of imatinib base and preparation of salts thereof
EA024088B1 (en) * 2010-06-18 2016-08-31 КРКА, д.д., НОВО МЕСТО Alpha-form of imatinib mesylate, processes for preparation thereof and pharmaceutical composition comprising the same
WO2012015999A3 (en) * 2010-07-29 2012-08-30 Dr. Reddy's Laboratories Ltd. Process for the preparation of imatinib mesylate
WO2012014000A1 (en) * 2010-07-30 2012-02-02 Ramesh Babu Potluri STABLE α-CRYSTAL FORM OF IMATINIB MESYLATE AND PREPARING PROCESS THEREOF
US8871930B2 (en) 2010-11-30 2014-10-28 Zhejiang Jiuzhou Pharma Science & Technology Co., Ltd. Preparation method of alpha-imatinib mesylate
WO2012071980A1 (en) * 2010-11-30 2012-06-07 浙江九洲药业股份有限公司 Preparation method of α-imatinib mesylate
US8912325B2 (en) 2011-03-31 2014-12-16 Ind-Swift Laboratories Limited Process for preparation of imatinib and its mesylate salt
EP2546247A1 (en) 2011-07-14 2013-01-16 F.I.S.- Fabbrica Italiana Sintetici S.p.A. Imatinib mesylate preparation procedure
WO2013136141A1 (en) 2012-03-13 2013-09-19 Fresenius Kabi Oncology Ltd. An improved process for the preparation of alpha form of imatinib mesylate
EP2749557A1 (en) 2012-12-31 2014-07-02 Deva Holding Anonim Sirketi Process for preparation of alpha polymorph of imatinib mesylate from IPA and THF solvate forms of imatinib mesylate
EP3007699A4 (en) * 2013-06-12 2017-01-18 Shilpa Medicare Limited Crystalline imatinib mesylate process
EP2927223A1 (en) 2014-04-04 2015-10-07 F.I.S.- Fabbrica Italiana Sintetici S.p.A. Process for preparing imatinib and salts thereof, free of genotoxic impurity f

Also Published As

Publication number Publication date
WO2009151899A3 (en) 2010-02-25
EP2291366A2 (en) 2011-03-09
EP2291366A4 (en) 2012-06-06

Similar Documents

Publication Publication Date Title
WO2009151899A2 (en) Preparation of imatinib mesylate
US8269003B2 (en) Stable crystal form of imatinib mesylate and process for the preparation thereof
US20100087444A1 (en) Imatinib mesylate
US8507508B2 (en) Solid forms of pemetrexed
US20160194301A1 (en) Preparation of lenalidomide
US11034714B2 (en) Process of making regadenoson and novel polymorphs thereof
WO2013046229A1 (en) Novel salts of alogliptin
JPWO2018117267A1 (en) Salts of substituted piperidine compounds
CN102164913A (en) Crystalline forms of a 3-pyrrole substituted 2-indolinone malate salt
JP2022000462A (en) How to prepare epalrestat
US20110015247A1 (en) Novel crystalline form of carvedilol dihydrogen phosphate and related processes
CA2734965A1 (en) Novel crystalline form and processes for its preparation
WO2011158255A1 (en) Process for preparation of stable imatintb mesylate alpha form
CN115974803B (en) A crystal form of Pseudomon and its preparation method and use
CN113801189B (en) Crystal form of D factor retarder and preparation method thereof
WO2018233678A1 (en) Right-handed rabeprazole sodium compound and pharmaceutical composition thereof
JP2017530107A (en) Sodium-glucose cotransporter 2 inhibitor L-proline compound, and monohydrate and crystal of L-proline compound
JP2019529410A (en) Method for producing pure and stable crystalline raltegravir potassium type 3
US20120232038A1 (en) Crystalline forms of (3r, 3as, 6ar) - hexahydrofuro [2,3-b] furan-3-yl (1s,2r) - (1-{4-[ (diethoxyphosphoryl) methoxy] pheny1}-3-hydroxy-4- [4-methoxy-n- (2-methylpropyl) benzenesul - fonamido] butan-2-yl) carbamate
US11427528B2 (en) Fenofibrate crystalline form and manufacturing method thereof
EP2604596A1 (en) Polymorphs of imatinib
CN114040908A (en) Crystal form of factor XIa inhibitor and preparation method thereof
WO2019120250A1 (en) Novel crystal form of pimavanserin hemi-tartrate and method for preparing crystal form
CN111747899A (en) Azoxystrobin channel type solvate, co-crystal and preparation method thereof
HK1161593A (en) Crystalline forms of a 3-pyrrole substituted 2-indolinone malate salt

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09763190

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 2009763190

Country of ref document: EP

NENP Non-entry into the national phase in:

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 7813/CHENP/2010

Country of ref document: IN